Effectiveness of Pramipexole for Treatment-Resistant Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-09-30

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the effectiveness of pramipexole (Mirapex) in managing treatment-resistant depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stratified Pharmacological Approaches for Regulating Circuit-Level Effects

NCT07022405

Depression - Major Depressive Disorder

NOT_YET_RECRUITING PHASE2

The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

NCT00163059

Depressive Disorder, Major

COMPLETED PHASE2

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

NCT00035295

Major Depressive Disorder

COMPLETED PHASE3

Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

NCT06058039

Major Depressive Disorder

RECRUITING PHASE3

Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)

NCT00759395

Anxious Major Depressive Disorder

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Depression is a serious medical illness, for which various types of treatment have been developed. Both medications and therapies have proven effective in treating depression. However, some people with depression do not benefit from these treatments. New medications are needed for treating depression in those who have not responded to commonly used antidepressants. Pramipexole (Mirapex) is most often used for the treatment of Parkinson's disease, but has been reported to have antidepressant effects as well. This study will evaluate the effectiveness of pramipexole in treating depression in individuals that have not responded to other medications.

Participants in this double blind study will be randomly assigned to receive either pramipexole or placebo, in addition to their current medications, for 8 weeks. Treatment response will be assessed at the end of this phase by measuring symptoms of depression. At this time, those individuals who have responded to treatment will have the option to continue in a 6-month follow-up study. Participants will be seen monthly throughout the 6 months to assess treatment response. Participants who do not exhibit a response to treatment will be tapered off the medication. All participants will receive 3 months of follow-up care, regardless of their response to the medication.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sugar pill

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

sugar pill

Pramipexole

Group Type EXPERIMENTAL

Pramipexole (Mirapex)

Intervention Type DRUG

pramipexole 0.5mg tablets qd and titrated per protocol

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pramipexole (Mirapex)

pramipexole 0.5mg tablets qd and titrated per protocol

Intervention Type DRUG

Placebo

sugar pill

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meets diagnostic criteria for major depressive disorder
* Meets criteria for current major depressive episode
* Score of at least 18 on the Montgomery-Asberg Depression Rating Scale (MADRS) at the baseline visit
* Currently being treated with antidepressant monotherapy at an adequate dose for 6 weeks or willing to enter open lead-in treatment
* Agrees to use an effective form of contraception throughout the study

Exclusion Criteria

* Pregnant
* At risk for suicide or homicide
* Unstable medical illness (e.g., cardiovascular, liver, kidney, respiratory, endocrine, or neurologic disease, including uncontrolled seizure disorder)
* History of a substance use disorder within 6 months of study enrollment
* History of or current psychotic features
* Currently being treated with typical or atypical antipsychotic medications
* Currently being treated with a medication known to significantly decrease pramipexole clearance (e.g., cimetidine, ranitidine, diltazem, verapamil, quinine or triamterene)
* Clinical or laboratory evidence of untreated hypothyroidism
* History of a 2-week or longer course of pramipexole
* Intolerance of pramipexole at any dose
* Any investigational psychotropic drug use within the last three months
* Level 3 or greater antidepressant resistance as assessed by the ATHF
* Three or more episodes of self-harm in the year prior to study enrollment
* Documented history of poor treatment adherence or frequently missed appointments
* Parkinson's disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No